Dr. Joel Schneider

Dr. Joel Schneider
Peptide Design and Materials
301-846-5954

Research Summary

The Schneider group designs and characterizes novel materials for use in tissue regenerative therapy, parenteral delivery of therapeutics, delivery of cells, and antibacterial therapy. We are particularly interested in peptide and protein-based hydrogel materials formed by self-assembly mechanisms. Our work spans molecular conception, materials synthesis, nano- and bulk mechanical materials characterization, cell-material interactions, biocompatibility, and assessment of performance efficacy. Our basic research establishes how material composition and structure influences material function, and lays the foundation to ultimately translate materials to the clinic.

Publications

1 - 5 of 77 results

1 2 3 4 5 ...

1) Johnson BC, Pauly GT, Rai G, Patel D, Bauman JD, Baker HL, Das K, Schneider JP, Maloney DJ, Arnold E, Thomas CJ, Hughes SH.
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.
Retrovirology. 9: 99, 2012. [Journal]

2) Sinthuvanich C, Veiga AS, Gupta K, Gaspar D, Blumenthal R, Schneider JP.
Anticancer beta-Hairpin Peptides: Membrane-Induced Folding Triggers Activity.
J. Am. Chem. Soc. 134: 6210-7, 2012. [Journal]

3) Gaspar D, Veiga AS, Sinthuvanich C, Schneider JP, Castanho MA.
Anticancer Peptide SVS-1: Efficacy Precedes Membrane Neutralization.
Biochemistry. 51: 6263-5, 2012. [Journal]

4) Veiga AS, Sinthuvanich C, Gaspar D, Franquelim HG, Castanho MA, Schneider JP.
Arginine-rich self-assembling peptides as potent antibacterial gels.
Biomaterials. 33: 8907-16, 2012. [Journal]

5) Geisler IM, Schneider JP.
Evolution Based Design of an Injectable Hydrogel.
Adv. Funct. Mater. 22: 259, 2012. [Journal]

A service of the National Cancer Institute